PTPRC and neoplasm: This preliminary analysis reveals a strong increase of circulating myeloid cells (CD45+CD3−CD19−CD56−HLA‐DR+ cells) in both PDAC patients and those with benign disease, compared to healthy individuals (Figure 1D).